WuXi AppTec Co Ltd H (2359) Fair Value & Analysis
Healthcare · HK · Market cap HK$455B (≈ $58.1B) · ISIN CNE100003F19
What is WuXi AppTec Co Ltd H really worth?
A strong business, but trading 27% above our fair value of HK$150.16.
Strengths
Risks
For context
Fair value as of: Sep 1, 2026
From 26 valuation models · updated 4 days ago
Fair value updated Sep 1, 2026, revised from HK$157.39 to HK$150.16 (−4.6%) since Aug 13, 2026. Share price +4.1% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- A high-quality business (quality 75/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety.
- The model range is unusually wide (HK$115.41 to HK$376.87). The outcome hinges heavily on assumptions, so read the point estimate with caution.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 1, 2026.
How to read this chart
60‑month range HK$26.71 – HK$206.60 · fair‑value band HK$115.41 – HK$376.87 · the HK$191.10 price screens above the HK$150.16 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 1, 2026.
Analysis
WuXi AppTec Co Ltd H (2359) currently trades at HK$191.10, while our model-based Fair Value estimate is HK$150.16, implying the stock looks roughly 27.3% overvalued today. The Quality Score stands at 75/100 (high quality), in the Healthcare sector. Bull case: the Growth Earnings group reads highest at a median of HK$251.00 per share, and 6 of the 26 models we run sit above the HK$191.10 price. Bear case: the Asset-Based group reads lowest at HK$22.42, and 20 of the 26 models stay below the price. Evidence for this calculation is high.
Over the trailing twelve months, WuXi AppTec Co Ltd H generated revenue of HK$46.2B at a net margin of 43.6%. Revenue grew 28.8% year over year. It earns a return on equity of 25.7%. The balance sheet holds a net cash position of HK$26.9B. Fundamentals as of Sep 1, 2026
Our scenario range runs from HK$115.41 (bear case) to HK$376.87 (bull case); at HK$191.10, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high and 150% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −54% fair-value upside, at −21%, 2359 screens cheaper than that median.
Fair Value models
This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly HK$3.43 per share, which is 2.3 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 26 models by family
Widest divergence: Growth Earnings (HK$251.00) versus Asset-Based (HK$22.42). Highest evidence: FCF DCF (76).
Notify me when 2359 reaches fair value
Put 2359 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Sep 1, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 73 · Market factors (momentum, volatility) 90
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs in the People's Republic of China, the United States, Europe, and internationally. The company operates through WuXi Chemistry, WuXi Testing, WuXi Biology, and Others segments.
Full company description
WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs in the People's Republic of China, the United States, Europe, and internationally. The company operates through WuXi Chemistry, WuXi Testing, WuXi Biology, and Others segments. It offers contract research, development, and manufacturing organization (CDRMO) services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions which support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides laboratory testing services, such as toxicology, DMPK, and bioanalytical services; clinical contract research organization services, including Phase I to Phase IV clinical development services, and bioequivalence for products including pharmaceuticals and biologics; and site management organization, patient recruitment, site start-up, and academic research organization. In addition, it offers services for biology; CDRMO platform for small molecules, oligonucleotides, and peptides; drug research and development testing; and clinical research services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
WuXi AppTec Co Ltd H reported revenue of 45.5B CNY in FY2025 versus 22.9B CNY in FY2021, a compound +18.7%/yr. Reported net income was 19.2B CNY in FY2025, compounding +39.2%/yr from FY2021.
of which total revenue +26.4 % · buybacks/dilution −3.5 %
Annual growth per factor. These are factors, not summands: multiplied they give the EPS growth rate, added they do not quite. Start and end points are 3-year averages (details on hover).
2359 screens 27% overvalued. Compare with Thermo Fisher Scientific Inc →
Recent news
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.
- Wuxi Apptec Co Ltd. - Sponsored ADR (WUXAY) Is a Great Choice for 'Trend' Investors, Here's Why
- Here's Why Momentum in Wuxi Apptec Co Ltd. - Sponsored ADR (WUXAY) Should Keep going
- Judge blocks US decision to add WuXi to list of firms tied to Chinese military
- WuXi AppTec Delivers Strong H1 2026 Results and Raises Full-Year Guidance[1], Driven by Greater Success of Multiple Customers' Products and
Peer Group
Diagnostics & Research · 130 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Diagnostics & Research median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Sep 1, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $630.70 | $308.19 | −51% |
| Danaher Corporation DHR | $215.68 | $103.88 | −52% |
| Lonza Group LONN | CHF 576.60 | CHF 259.80 | −55% |
| IDEXX Laboratories, Inc IDXX | $556.69 | $255.77 | −54% |
| Agilent Technologies, Inc A | $149.93 | $61.53 | −59% |
| Waters Corporation WAT | $416.15 | $121.96 | −71% |
| IQVIA Holdings IQV | $236.66 | $132.17 | −44% |
| Illumina, Inc ILMN | $215.59 | $95.51 | −56% |
| Mettler-Toledo International Inc MTD | $1,419 | $615.78 | −57% |
| Quest Diagnostics Incorporated DGX | $242.76 | $162.50 | −33% |
Compare WuXi AppTec Co Ltd H with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is WuXi AppTec Co Ltd H (2359) overvalued or undervalued?
What is the fair value of 2359?
What is the quality score of 2359?
What is the revenue of WuXi AppTec Co Ltd H (2359)?
What is the net profit margin of 2359?
Does WuXi AppTec Co Ltd H pay a dividend?
Watch WuXi AppTec Co Ltd H in the live analysis
One click puts WuXi AppTec Co Ltd H on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.